Programmed Death-Ligand (Immune Checkpoint Ligands)

Programmed death-ligand 1 (PD-1) serves as an important immunocheckpoint receptor that is actively studied in the context of clinical cancer immunotherapy¹.
PD-L1, an important PD-1 ligand is widely expressed and is frequently overexpressed by tumor cells thereby limiting T cell activity and blocks antitumor immune responses^1,2.
AnaSpec/EGT group offers readily available catalog PD-L1 inhibitor peptides for cancer immunotherapy research (blockade/inhibitor peptides against PD-1/PD-L1 interaction).

PD-L1 Inhibitor Peptides

PD-L1 Inhibitor I

PD-L1 Inhibitor II

PD-L1 Inhibitor III

PD-L1 Inhibitor IV

PD-L1 Inhibitor V

PD-L1 Inhibitor Peptides
PD-L1 Inhibitor I
PD-L1 Inhibitor II
PD-L1 Inhibitor III
PD-L1 Inhibitor IV
PD-L1 Inhibitor V

Immunomodulation Schemes

Anti-Cancer Immunosurveillance

Tumor antigens (on tumor cells) are recognized by Dendritic cells
Dendritic cells capture & present tumor antigens to T-cells
Activated T-cells bind to tumor cells
T-cells release cytokines & cause cell death

Immunosuppression via PD-L1

Tumor cells overexpress PD-L1.
PD-1 receptor expressed on activated T-cells binds to PD-L1 expressed on dendritic cells
T-cells get downregulated; cytokines production reduces
Tumor cell proliferates exhibiting immunotolerance

PD-L1 Inhibitor Peptides
AnaSpec/EGT Group offers peptide inhibitors (peptide ligands) that target human PD-1 (hPD-1). The peptide ligands contain sequences with key anchor residues that impact the binding of PD-L1 ligands to hPD-1.

Catalog #	Product	Sequence	Size
AS-65581	Human PD-L1 Inhibitor I	FNWDYSWKSERLKEAYDL	1 mg
AS-65582	Human PD-L1 Inhibitor II	FNWDYSLEELREKAKYK	1 mg
AS-65583	Human PD-L1 Inhibitor III	TEKDYRHGNIRMKLAYDL	1 mg
AS-65584	Human PD-L1 Inhibitor IV	GNWDYNSQRAQLYNQ	1 mg
AS-65585	Human PD-L1 Inhibitor V	LDYVNRRKMYQ	1 mg

Related Products

Cancer Research Peptides

References
1) Keir ME, et al. D-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007;19(3):309-14.
2) Li Q, et al. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget. 2016;7(40):64967-64976.

Richiedi un'offerta

DBA-ITALIA Srl
Via Umbria 10
20090 Segrate (Milano)

Tel. +39 02-26922300
Fax +39 02-26926058
Fax +39 02-26923535

If you no longer wish to receive these announcements click here